appropriation of profits

[et_pb_section fb_built=“1″ _builder_version=“3.22″][et_pb_row _builder_version=“3.25″ background_size=“initial“ background_position=“top_left“ background_repeat=“repeat“][et_pb_column type=“4_4″ _builder_version=“3.25″ custom_padding=“|||“ custom_padding__hover=“|||“][et_pb_text _builder_version=“4.4.6″ hover_enabled=“0″]

Ad-hoc of HAEMATO AG:

The Supervisory Board of HAEMATO AG (ISIN: DE0006190705) approved today’s proposal for the appropriation of profits by the Management Board in today’s balance sheet meeting. Accordingly, the Management will propose to the Annual General Meeting on July 8, 2020 to carry forward the 2019 financial year remaining net income to new account.



HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of its business activities is on the growth markets of high-priced specialty pharmaceuticals. The focus is on therapies for cancer, HIV and other chronic diseases.


HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures of the HAEMATO AG share:

Subscribed capital: EUR 22,867,154

Listed class of shares: Bearer ordinary shares

ISIN: DE0006190705

WKN: 619070

Stock exchange code: HAE


Go back

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us